Bright Minds Biosciences (NASDAQ: DRUG) will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 4:20 PM EDT, with a live and archived webcast available on its investor website for 30 days.
The company also granted 109,000 stock options to directors, officers and consultants, exercisable at US$83.40 per share for five years, vesting in four equal annual 25% installments starting one year from grant.
On the day this news was published, DRUG gained 0.88%, reflecting a mild positive market reaction.
Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
This price movement added approximately $8M to the company's valuation, bringing the market cap to $902.71M at that time.
This announcement combines an investor-relations update with an equity compensation action. DRUG wil...
Analysis
This announcement combines an investor-relations update with an equity compensation action. DRUG will present at Jefferies on June 3, 2026, extending its recent pattern of conference visibility, while granting 109,000 stock options at US$83.40 vesting over four years. Earlier in 2026, the company completed sizeable equity offerings and attracted multiple Schedule 13G/A filings from institutional holders. Investors may watch future financing decisions, insider activity, and clinical milestones to contextualize these moves.
Key Figures
Options granted:109,000 sharesOption exercise price:US$83.40 per shareOption term:5 years+5 more
8 metrics
Options granted109,000 sharesNew stock options to directors, officers and consultants
Option exercise priceUS$83.40 per shareExercise price for newly granted options
Option term5 yearsValidity period from grant date
Vesting schedule4 instalments of 25%Annual vesting beginning on first anniversary
Conference dateJune 3, 2026Jefferies Global Healthcare Conference presentation
Conference time4:20 PM EDTScheduled presentation time
Launched US$100M public offering with 15% underwriter option.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent equity offerings for DRUG often coincided with short-term share price pressure, while a later offering-related headline saw a positive reaction, indicating mixed follow-through.
Recent Company History
Over the last six months, DRUG’s notable events centered on financing and investor outreach. In early January 2026, the company launched, priced, and closed a public offering totaling gross proceeds of US$175,050,000, which generally saw negative price reactions. A February 25, 2026 update highlighted multiple upcoming conference presentations, with shares down 5% over 24 hours. Today’s Jefferies presentation and option grant continue the pattern of capital markets visibility and equity-related corporate actions.
Key Terms
5-ht2 agonists, prader-willi syndrome, central nervous system (cns), stock options
4 terms
5-ht2 agonistsmedical
"focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy"
Drugs described as 5-HT2 agonists are medicines that act like a key fitting into a specific serotonin receptor (the 5-HT2 family) to switch that receptor on. Investors care because turning these receptors on can produce therapeutic effects (for conditions like mood, appetite or sleep) but also carries distinct safety and regulatory risks tied to which 5-HT2 subtype is affected, so trial results and approvals can strongly move a company’s value.
prader-willi syndromemedical
"for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other"
A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.
central nervous system (cns)medical
"depression, and other central nervous system (CNS) disorders, today announced that"
The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.
stock optionsfinancial
"the Company has granted stock options (the “Options”) to certain directors, officers"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the Jefferies Global Healthcare Conference as follows:
Bright Minds further releases that the Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate of 109,000 common shares in the capital of the Company (the “Shares”) pursuant to the Company's share option plan. The Options are exercisable at a price of US$83.40 per Share for a period of five (5) years from the date of grant. The Options vest in four (4) equal annual instalments of 25% each, commencing on the first anniversary of the date of grant.
About Bright Minds Biosciences
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Alex Vasilkevich Chief Operating Officer Bright Minds Biosciences Inc. T: 414-731-6422 E: alex@brightmindsbio.com
FAQ
When will Bright Minds Biosciences (NASDAQ: DRUG) present at the Jefferies Global Healthcare Conference 2026?
Bright Minds Biosciences is scheduled to present on Wednesday, June 3, 2026, at 4:20 PM EDT. According to the company, investors can access a live and archived webcast of the presentation on its investor relations website under Events and Presentations.
How can investors access the Bright Minds Biosciences (DRUG) Jefferies Global Healthcare Conference webcast?
Investors can watch the Bright Minds presentation via a live webcast available on the company’s investor site. According to Bright Minds, an archived replay of the Jefferies Global Healthcare Conference webcast will remain accessible for 30 days under Events and Presentations.
What stock options did Bright Minds Biosciences (DRUG) grant on May 26, 2026?
Bright Minds granted options to purchase 109,000 common shares to certain directors, officers and consultants. According to the company, these options are exercisable at US$83.40 per share for five years, with vesting in four equal annual 25% installments beginning one year from the grant date.
What is the vesting schedule for the new Bright Minds Biosciences (DRUG) stock option grant?
The granted options vest in four equal annual installments of 25% each. According to Bright Minds, vesting starts on the first anniversary of the grant date and continues annually, fully vesting after four years if conditions are satisfied.
What is the exercise price and term of the new Bright Minds Biosciences (DRUG) options?
The newly granted stock options have an exercise price of US$83.40 per common share and a five-year term. According to Bright Minds, holders may exercise these options any time within that period, subject to the vesting schedule and applicable plan conditions.
